Kelly Tseng, (Life Sciences) is the recipient of a new sponsored research program with Provectus Biopharmaceuticals, a clinical-stage biotechnology company. The project is to investigate and characterize the effects of Provectus' drug product on vertebrate tissue regeneration and repair.
